Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study

BACKGROUND: Patients with severe COVID-19 develop a life-threatening hyperinflammatory response to the virus. Interleukin (IL)-1 or IL-6 inhibitors have been used to treat this patient population, but the comparative effectiveness of these different strategies remains undetermined. We aimed to compa...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Lancet Rheumatol
Egile Nagusiak: Cavalli, Giulio, Larcher, Alessandro, Tomelleri, Alessandro, Campochiaro, Corrado, Della-Torre, Emanuel, De Luca, Giacomo, Farina, Nicola, Boffini, Nicola, Ruggeri, Annalisa, Poli, Andrea, Scarpellini, Paolo, Rovere-Querini, Patrizia, Tresoldi, Moreno, Salonia, Andrea, Montorsi, Francesco, Landoni, Giovanni, Castagna, Antonella, Ciceri, Fabio, Zangrillo, Alberto, Dagna, Lorenzo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier Ltd. 2021
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7906668/
https://ncbi.nlm.nih.gov/pubmed/33655218
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2665-9913(21)00012-6
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak